UBS AM
PLRX icon

UBS AM’s Pliant Therapeutics PLRX Stock Holding History

UBS AM’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-154,906
Closed -$209K – 2700
2025
Q1 		$209K Buy
154,906
+15,332
+11% +$93.1K ﹤0.01% 2577
2024
Q4 		$1.84M Buy
139,574
+21,637
+18% +$295K ﹤0.01% 2092
2024
Q3 		$1.32M Buy
117,937
+455
+0.4% +$5.69K ﹤0.01% 2250
2024
Q2 		$1.26M Buy
117,482
+45,363
+63% +$585K ﹤0.01% 2255
2024
Q1 		$1.07M Buy
72,119
+8,400
+13% +$139K ﹤0.01% 1972
2023
Q4 		$1.15M Hold
63,719
– – ﹤0.01% 1952
2023
Q3 		$1.1M Buy
63,719
+30,100
+90% +$522K ﹤0.01% 1907
2023
Q2 		$894K Hold
33,619
– – ﹤0.01% 2056
2023
Q1 		$894K Buy
33,619
+20,019
+147% +$570K ﹤0.01% 2056
2022
Q4 		$263K Buy
+13,600
New +$284K ﹤0.01% 2369
2022
Q2 		– Sell
-15,199
Closed -$107K – 2750
2022
Q1 		$107K Buy
+15,199
New +$155K ﹤0.01% 2737

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

UBS AM's PLRX Position: Q2 2025 in Review

UBS AM sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 154,906 shares — an estimated $209K sold.

UBS AM first reported a position in PLRX in Q1 2022 and held it in 11 quarters. The position peaked at $1.84M in Q4 2024. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • UBS AM reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 154,906 Pliant Therapeutics shares in Q2 2025, an estimated $209K.
  • UBS AM first reported a position in Pliant Therapeutics in Q1 2022 and held it in 11 quarters.
  • UBS AM's Pliant Therapeutics position peaked at $1.84M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.